Analysis of Factors Influencing Clinical Efficacy of Rituximab on Patients with Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2020.04.021
- Author:
Min ZHONG
1
;
Qun-Hao SU
2
;
Lu XU
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Hainan Medical College, Haikou 570102, Hainan Province, China,E-mail: hyfyxynko@163.com.
2. Department of Hematology, The First Affiliated Hospital of Hainan Medical College, Haikou 570102, Hainan Province, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Cyclophosphamide;
therapeutic use;
Doxorubicin;
therapeutic use;
Herpesvirus 4, Human;
Humans;
Lymphoma, Large B-Cell, Diffuse;
drug therapy;
Prednisone;
therapeutic use;
Rituximab;
therapeutic use;
Treatment Outcome;
Vincristine;
therapeutic use
- From:
Journal of Experimental Hematology
2020;28(4):1210-1214
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical efficacy and safety of rituximab therapy for patients with Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL), and to explore the factors influencing the clinical efficacy.
METHODS:According to therapeutic regimen, 66 patients with EBV-positive DLBCL were divided into two groups: CHOP group (32 cases) and R-CHOP group (CHOP+ rituximab, 34 cases). The clinical efficacy and the incidence of complication were compared between two groups. The clinical risk factors for the clinical efficacy in patients with EBV-positive DLBCL were confirmed by multivariate Logistic analysis.
RESULTS:Compared with CHOP group, the complete remission rate, partial remission rate and the overall effective rate in R-CHOP group all were high (P＜0.05), moreover the disease progression rate in R-CHOP group were low (P＜0.05). The occurrences rate of myelotoxicity, hepatic injury and gastrointestinal reaction were not statistically significantly different between two groups (P＞0.05). Multivariate Logistic analysis showed that the Ann Arbor staging, IPI risk score and Ki-67 positive rate were independent risk factors for the clinical efficacy in patients with EBV-positive DLBCL (OR=2.689, P=0.038; OR=3.232, P=0.025; OR=2.919, P=0.023).
CONCLUSION:The clinical efficacy and safety of the therapy with rituximab on the patients with EBV-positive DLBCL are better. The poor Ann Arbor stage, high IPI risk score and the Ki-67 positive rate are factors affecting the clinical efficacy for the patients with EBV-positive DLBCL.
